Intra-Cellular Hid Drug Issues Before FDA Probe, Suit Says
A putative class of Intra-Cellular Therapies Inc. investors on Friday in New York federal court accused the biopharmaceutical company of concealing safety concerns about its new schizophrenia medication lumateperone, saying that...To view the full article, register now.
Already a subscriber? Click here to view full article